underappreci revenu opportun initi
initi coverag inc outperform rate price
target believ pfnx base busi strateg partnership provid potenti
near-term revenu clinic valid proprietari technolog platform
posit compani fund emerg pipelin evolv partnership-
base busi model one wholly-own asset partner launch next
month could includ osteoporosi hematolog
infectious-diseas vaccin believ revenu potenti fulli
reflect current trade level note catalyst next month includ
potenti registration-en data potenti
launch longer term believ manag may opt select
invest wholly-own asset gener organ growth
posit strong us launch view approv fda
partner alvogen well posit obtain share
lli forteo may also benefit overal market growth osteoporosi
agent estim address us revenu opportun
model launch world-wide revenu royalti
key contributor valu
partnership present long-term upsid licens
agreement merck suppli carrier protein use mrk
pneumococc conjug vaccin could launch
us market approv believ may earn mileston royalti
net sale risk-adjust opportun model royalti
reach sever million
express technolog base strain pseudomona fluorescen
cost-effect produc larg amount protein pfnx exist partnership
base pipelin asset origin platform technolog
manag indic cash flow initi asset posit compani
fund on-going effort creat wholly-own pipelin
catalyst includ phase studi readout
prevent pneumococc diseas siipl launch pneumosil
pivot phase interim analysi
bla file shortli thereaft therapeut equival decis
fda us launch eu launch
year price histori
focus develop
vaccin use proprietari platform
osteoporosi
hypersensit coli regimen
analyst certif import disclosur see disclosur
believ pfnx solid base busi strateg partnership
clinic valid proprietari technolog platform posit
compani growth long-term partner
launch next month could includ
osteoporosi hematolog infectious-
fulli reflect current trade level
outperform rate reflect view lead asset
may launch address us market opportun
registration-en data two
partnership could drive meaning upsid current level
longer term believ manag may opt
select invest wholly-own asset gener organ
achiev therapeut equival launch
achiev sale provid royalti stream
gross profit probabl
launch provid royalti
stream net sale probabl
approv launch provid
royalti stream net sale probabl
total oper expens per year short term
grow outer year
phase studi readout prevent
pneumococc diseas
siipl launch pneumosil
pivot phase interim analysi
therapeut equival decis fda
us launch
eu launch
higher expect sale
faster anticip launch uptak and/
pipelin expans
achiev therapeut equival
fail launch
gener forteo competitor enter us market sooner anticip
failur achiev approv lower royalti
price target base blend discount cash flow sum-of-the-part analys model royalti product candid
ten-year period assum termin valu base tail market product project period discount
cash flow use discount rate believ approxim compani weight averag cost capit base
risk-fre rate expect market return beta per bloomberg assum termin growth rate
revenu retain termin period
achiev therapeut equival gener forteo competitor enter us market sooner anticip failur
achiev approv and/or dilut financ
inc platform-bas biopharmaceut compani use
proprietari protein product platform pfnex express technolog develop next
gener novel protein therapeut leverag technolog platform
enabl effort gener revenu out-licens earli clinic stage
asset pharmaceut compani clinic develop commerci
pfnx histor revenu exhibit consist payment partner form
upfront/mileston payment servic revenu note histor variabl
revenu primarili driven time deal payment
manag plan leverag pfnex express technolog platform develop
portfolio wholly-own novel therapeut believ posit compani
long-term valu creation given platform histor success rate express
natur engin protein may well posit expand pipelin
evolv tradit biotechnolog compani addit partner
asset develop wholly-own recombin peptid preclin
productpartnerregionphasepartnership termspotenti milestonesnotesalvogenusapprov await te decis launchup gross te metup launch alvogen upon fda decis te rate alvogen theramexeumaa filedup gross profitup approv earli sajamenamaa filedup gross profitup submit saudi arabia saudi food drug author sfda alvogen jamp pharmacanadaup gross profitalvogen kamadaisrealup gross profitalvogen pharmbio koreasouth koreaup gross profitalvogenrow ex-region licens nt pharma gross profitup pharmachina hong kong malaysia singapor thailanddouble-digit royalti net salesup payment certain develop regulatori sales-rel pharmaceuticalsworldwidephas net salesup submiss earli pharmaceuticalsworldwidepreclinicalti net phase trial ongoingsingl digit net salesdevelop submiss expect earli end addit product pneumosil serum institut india privat limit siipl indiasubmit phase data drug control gener india dcgi singl digit net sale siipl provid reagant grade cgmp potenti mainten mileston feespneumosil achiev prequalif decemb prequalif allow product procur unit nation agenc gavi vaccin meningococc conjug vaccin serum institut india privat limit siipl develop marketsphas ongingsingl digit net sale siipl provid reagant grade cgmp potenti mainten mileston sparx sparx net product use technolog complet develop sparx sparx arcellx opt commerci licens product strain also receiv develop fund inc
manag alreadi highlight sever clinic regulatori catalyst
exhibit import view phase interim
analysi potenti bla file phase data potenti
bla file therapeut equival decis fda subsequ
us launch eu launch
productpartnerpotenti pharmaceuticalspivot phase trial interim pharmaceuticalsbla studi color closer ind equival decis outperform
believ pfnx could first-to-market therapeut equival non-
brand altern forteo us revenu opportun forteo remain
prescrib anabol agent osteoporosi manag us even
new product launch last three year exhibit model launch
us revenu grow thereaft
note ltm march
osteoporosi diseas character low bone mass structur deterior
bone tissu lead greater fragil increas fractur risk diseas
progress accord nation osteoporosi foundat estim million
peopl us alreadi osteoporosi anoth approxim million
low bone mass place increas risk osteoporosi age popul
primari driver increas case osteoporosi also increas use
drug induc bone loss glucocorticoid aromatas inhibitor
osteoporosi drug segment two class antiresorpt agent
prevent bone loss inhibit breakdown bone anabol agent
stimul bone format build new bone anabol agent teriparatid
parathyroid hormon potent antiresorpt agent bisphosphon denosumab
improv bone miner densiti bmd reduc risk fractur treatment-nav
accord industri refer patient us treat osteoporosi
drug patient treat anabolic-ag includ forteo tymlo
even amgn/ucb exhibit
forteo recombin human pth analog first approv anabol
therapeut agent remain treatment option pharmacolog class
launch tymlo total anabol market grew
new launch continu grow market overal declin primarili driven
lower forteo script potenti discontinu activ forteo promot
histor forteo trx remain gener flat per year exhibit
note ltm march
estim us market size launch rang base
address script exhibit
view approv fda octob well posit get
market share lli forteo upon launch may also experi benefit
overal market growth driven new launch
summar data studi enrol patient primari
endpoint anti-drug antibodi ada level week drug treatment exhibit
vitro neutral activ detect pharmacolog activ assess chang bmd btm observ studi patient
note antibodi titer measur much ada present posit sampl valu lowest possibl find wherea valu repres increas
secondari endpoint includ mean percentag chang lumbar-spin bone
miner densiti bmd median percentag chang bone turnov marker btm
week drug treatment well pharmacokinet paramet four
hour first dose forteo demonstr compar effect lumbar-
spine bmd n-termin propeptid type procollagen marker
bone format cross-link c-termin telopeptid type collagen
marker bone resorpt statist signific differ
paramet forteo lumbar-spin bmd btm result
shown exhibit
lowhighaddress gross-to-net price per revenu opportun forteo week studi overal anti-drug antibodi resultstim studi anti-drug antibodi titer result individu patientsnumb percent patient treatment-rel ae lead earli ae lead treatment-emerg advers event profilesgrad studi sever treatment-emerg advers event inc
bioequival demonstr clinic studi healthi
us label ident forteo exhibit note label
trade name bonsiti await rate therapeut equival
forteo event achiev rate trade name would remov
exhibit forteo bonsiti label comparison
drug product consid therapeut equival follow criteria met
pharmaceut equival contain ident amount activ
drug ingredi dosag form rout administr meet
applic standard strength qualiti puriti ident
bioequival
broadli two type therapeut equival code a-rat b-rate a-rat
drug fda consid therapeut equival therefor
substitut permit prescrib second letter code provid
inform dosag form case result fda evalu
actual potenti bioequival problem exampl achiev aa-rat
drug must prove ingredi dosag form present actual potenti
bioequival problem wherea achiev ab-rat drug actual potenti
bioequival problem resolv adequ in-vivo and/or in-vitro
test orang book code system interpret describ exhibit
aa rate would allow drug product automat substitut
approv drug product therapeut equival evalu known orang book
submit result compar use human factor cuhf studi drug-
devic combo equival along data support pharmaceut equival
show activ ingredi strength/concentr dosag form rout
administr bioequival fda octob
studi includ total untrain particip includ osteoporosi patient
caregiv critic task perform patient user group
perform caregiv group fewer equal user
error ue compar forteo instanc margin
higher user error rate critic task perform patient user group
critic task perform caregiv user group magnitud
differ ue ue respect exceed predetermin
maximum allow differ either user group exhibit
therapeut equival fda coderequirementsdefinitionaano bioequival problem convent dosag formscontain activ ingredi dosag form regard present either actual potenti bioequival problem drug qualiti standard issu abmeet necessari bioequivalec requirementsmeet necessari bioequival requir vivo and/or vitro test compar refer drug code ab specif product head consid therapeut equival drug code ab head thu product categori consid gener drug circumst may ab-rat gener product use patent brand name refer standard ansolut powder aerosolizationuncertainti regard therapeut equival aerosol product aris primarili differ drug deliveri system solut powder intend aerosol market use sever deliveri system consid pharmaceut therapeut equival code aoinject oil soultionsth absorpt drug inject parenter oil solut may vari substanti type oil employ vehicl concentr activ ingredi inject oil solut therefor consid pharmaceut therapeut equival activ ingredi concentr type oil use vehicl ident apinject aqueou solutionsit note even though inject parenter product specif list may evalu therapeut equival may import differ among product gener categori inject inject exampl inject product rate therapeut equival label differ rout administr attop productsdiffer topic dosag form may contain activ ingredi potenc dosag form consid pharma- ceutic equival therefor consid therapeut equival solut desi drug product contain activ ingredi topic dosag form waiver vivo bioequival grant chemistri manufactur process adequ consid therapeut equival code b-ratednot bioequival avail formulationsnot therapeut equival due actual potenti bioequival problem resolv thissect often relat pharmacokinet differ aris due product dissolut disintegr absorpt metabol link specif deliveri form rather safeti efficaci outperform
april announc fda inform alvogen addit
compar use human factor studi specif forteo experienc user would
requir te could determin anticip new trial protocol
larg similar previou cuhf studi expect detail later year
ascrib value-per-share
royalti revenu key valu driver valuat framework account
price target value-per-share base net present valu tax-
affect gross profit royalti net proport share oper
expens cash model royalti revenu grow
exhibit royalti estim assum therapeut equival grant
us launch eu launch
model anabol agent script market growth yoy assum two market
gener forteo includ middl decad estim
achiev share total forteo market grow share
exhibit declin thereaft assum addit gener approv
exhibit estim market share forteo script
note market share calcul use total forteo script respect year
model price wac
discount lli wac
note discount
rebat could posit product
competit price advantag rel
brand product includ
growth calcul last price chang per price rx
us opportun drive major valu may launch ou
market multipl gener includ gener teriparatid market stada
western europ gideon richter eastern europ model ou revenu
reach us revenu time partnership term list exhibit
productpartnerregionphasepartnership termspotenti milestonesnotesalvogenusawait te decisionup gross te metup launch alvogen upon fda decis te rate alvogen theramexeumaa filedup gross profitup approv earli sajamenamaa filedup gross profitup submit saudi arabia saudi food drug author sfda alvogen jamp pharmacanadaup gross profitalvogen kamadaisrealup gross profitalvogen pharmbio koreasouth koreaup gross profitalvogenrow ex-region licens nt pharma gross profitup pharmachina hong kong malaysia singapor thailanddouble-digit royalti net salesup payment certain develop regulatori sales-rel forteo effect datewacdiscount datewacdiscount datewacdiscount packag alvogen packag pricetymlo packag price outperform
licens agreement merck product suppli
non-tox mutant diphtheria toxin serv carrier protein
therapeut prophylact vaccin use
pneumococc conjug vaccin registration-en trial approv
believ may elig earn mileston payment royalti net
address market opportun may substanti exhibit
note market current serv mrk pneumovax
expect registration-en data late potenti us/eu
approv launch mid- adult pediatr
unadjust sale reach exhibit
may present key advantag current market vaccin two new
serotyp includ remain conserv market share
assumpt peak script share note develop
next-gener polysaccharid conjug vaccin cover serotyp includ
five addit serotyp exhibit present overview variou
exhibit overview pneumococc vaccin serotyp
ascrib value-per-share partnership
partnership account price target value-per-share
base net present valu tax-effect gross profit royalti reduc
proport share net oper expens cash model margin royalti
grow exhibit royalti estim assum royalti
rate probabl reach revenu estim
note may also elig potenti mileston fee incorpor
signific unmet need
partner label recombin erwinia
asparaginas current registration-en trial treat patient acut
lymphoblast leukemia hypersensit current treatment regimen
includ l-asparaginas deriv coli oncaspar servier jazz erwinaz
asparaginas deriv erwinia chrysanthemum plant approv treat
patient product take approxim nine month manufactur
experienc signific suppli issu last sever quarter believ
approv could address immedi unmet need among
patient estim could address market opportun
us eu exhibit fda grant track design
plan file bla
type cancer white blood cell call lymphocyt produc
bone marrow dna mutat caus cell bone marrow continu multipli
produc malign immatur cell call lymphoblast may spill
peripher circul immatur cell develop cancer white blood cell
red blood cell white blood cell platelet compromis immun
treat chemotherapi target drug therapi chemotherapi use
induct therapi kill leukemia cell blood bone marrow consolid
therapi destroy leukem cell remain blood spinal cord and/or
mainten therapi prevent recurr leukemia cell requir amino-acid call
asparagin grow multipli therefor asparaginas enzym break
asparagin use conjunct chemotherapi remov asparagin inhibit
three form asparaginas includ l-asparaginas natur occur un-
modifi enzym deriv coli peg-asparaginas pegyl version l-
asparaginas longer half-lif erwinia asparaginas deriv erwinia
chrysanthemum plant l-asparaginas peg-asparaginas therapi
patient experi hypersensit treat erwinaz
erwinia asparaginas typic use therapi exhibit
exhibit region use asparaginas
erwinaz market gener annual revenu global exhibit
suppli inconsist due manufactur hurdl cgmp violat
notic januari experienc jazz sole supplier porton biopharma limit
pbl wholli own entiti uk depart social april
pbl announc partnership clinigen clin commerci erwinaz
global begin termin pbl contract believ
posit launch upon approv
believ could resolv erwinaz suppli ineffici potenti
improv clinic profil less immunogen current phase pivot trial
assess efficaci toler patient all/lbl hypersensit coli-
deriv asparaginas allerg reaction silent inactiv exhibit plan
conduct interim analysi may submit bla model
launch revenu reach exhibit
estim enrol inclus criteriapediatr adult patient diagnosi lblhave allerg reaction long-act coli-deriv asparaginas silent inactivationhav cours coli-deriv asparaginas remain his/her treatment planpati must opinion investig fulli recov prior allerg reaction coli-deriv asparaginaseselect exclus criteriahav previous receiv asparaginas erwinia chrysanthemi relaps lblare concurr receiv anoth investig agent and/or treat investig devic time within hour cours histori grade pancreatitisprior histori asparaginase-associ grade hemorrhag event asparaginase-associ thrombu requir anticoagul therapi exclud catheter-rel thrombot eventsdesign timelinetwo week cours intramuscular im administr follow-up last cours dose primaryendpointsproport patient last nsaa level iu/ml occurr treatment-emerg advers event secondaryendpointsproport patient last nsaa level iu/ml proport patient last nsaa level iu/ml proport patient last nsaa level iu/ml serum asparaginas activ level first cours incid anti-drug antibodi format estim us sales sale outperform
model royalti grow exhibit royalti
also model approv mileston payment note may
receiv addit regulatory-rel mileston payment
sales-rel mileston model
target price base blend discount cash flow exhibit sum-
of-the-part exhibit analys model royalti sale
franchis ten-year period assum termin valu base
tail market product project period assumpt underli
price target
us launch probabl aa-rat allow automat
substitut forteo script pharmaci anabol script market
share model us gross profit share ou share
world-wide launch probabl success price pariti
current erwinaz regimen model global royalti rate net sale
world-wide launch peak share pneumococc
vaccin market outer year model global royalti rate net
estim oper expens reach next year grow
outer year
discount cash flow year-end use discount rate
believ approxim compani weight averag cost capit base
risk-fre rate expect market return beta
termin growth rate revenu retain termin
valu asset base npv tax-effect gross profit
includ sg capit expenditur chang work capit
after-tax work cash flow pershar discountr present outperform
near-term risk consid
fail achiev therapeut equival
believ rate therapeut equival forteo may impact
valuat meaning would expect slower us revenu ramp
competit threat lower royalti rate us rate would declin gross
profit compani would receiv mileston payment
alvogen estim potenti neg impact price target
receiv therapeut equival statu exhibit
exhibit base downsid case
believ non-brand teriparatid market could becom three-play market
us exhibit assum teva launch gener equival forteo
apotex reach market event apotex launch earlier
expect and/or gener enter market note valuat could
would experi addit price pressur potenti lose market
share apotex launch earlier estim neg impact price target
apotex launch gforteo exhibit
base casedownsid case us script royalti typefil typeestim upon te decis teva anda referenc forteo manag note continu work fda gforteo launch could occur anda gener version forteo statu unknown inc
assum probabl approv model launch mid-
fail obtain approv abandon develop plan
estim neg impact price target note
attribut valu longer act erwinia asparaginas still earli
manag teamexperi educationeef schimmelpenninkchief execut offic alovtechchief execut officervic presid global steril inject pfizerpresidentvic presid global gener hospirasecretaryvic presid market sale synthon bvinterim chief officermast bioprocess engin wageningen universitymartin brenner ph chief scientif offic recurs pharmaceuticalschief scientif officervic presid head research earli develop stoke therapeut execut director diabet nash chair diabet nash earli discoveri merck research laboratori merck co senior director head bioscienc cvmd astrazenecaph pharmacolog veterinari school hannoverdvm veterinari school ludwig-maximilians-univers munichshawn scrantonchief scientif consult sentynl therapeut zydus-cadila chief oper officerchief scientif offic sentynl therapeuticsconsult manag director strateg therapeut solutionsr director translat medicin kalypsysdoctor pharmaci univers pacif school pharmaci anim physiolog univers california san diegopatrick lucyinterim chief execut offic presid secretari pfenexchief busi officervic presid busi develop market pfenexdirector busi develop pharma chemic group director busi develop collabor bioallianc acquir chemic group biolog villanova estim base casensid case outperform
quarterli revenu payment revenu changetot revenu revenuetot revenu pfenex inc
adjust non-gaap incom statement profit incom incom incom tax rate incom share chang total revenu outperform
stock price compani mention report
compani nyse cover
cash unbil receiv tax current current asset equip long-term asset asset portion defer portion capit leas current current liabil revenu less current leas oblig less current non-curr liabil sharehold equiti liabil sharehold equiti inc
